2. UroToday Home
  3. Video Lectures

Precision Medicine in Prostate Cancer

BRCAAway - a Randomized Phase 2 Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with mCRPC with DNA Repair Defects - Maha Hussain
August 2, 2022
Details
Impact of Next Generation Imaging: What Is the Optimal (Current) Tracer for PET-Based Imaging for Staging Presentation - Ken Herrmann
August 2, 2022
Details
Integrating 177Lu-PSMA-617 in Clinical Practice - Oliver Sartor
July 4, 2022
Details
The Use of PARP Inhibitors in Castrate-Resistant Prostate Cancer - Elena Castro & Joaquin Mateo
June 19, 2022
Details
Hereditary Cancer Risk Assessment For Prostate Cancer Patients - Neal Shore
April 12, 2022
Details
Integration of Pluvicto™ (177Lu-PSMA-617) in Clinical Practice - Oliver Sartor and Kendra Harris
April 7, 2022
Details
The Efficacy and Safety of Olaparib + Abiraterone in the First-Line mCRPC Setting PROpel – Fred Saad
March 4, 2022
Details
Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer – Kara Maxwell
February 4, 2022
Details
Genomic Profiling: Germline and Somatic Testing - What You Must Know Today - Emmanuel Antonarakis
December 16, 2021
Details
The Clinical Implications of The VISION Trial, PSMA-Targeted Radiotherapy in Metastatic Prostate Cancer - Michael Morris
August 12, 2021
Details
PSMA Molecular Targeted Radiation Therapy - Andrei H. Iagaru
May 10, 2021
Details
Demonstrating PSMA Molecular Diagnostic Imaging with18F-DCFPyL or 68Ga-PSMA11 for Prostate Cancer Staging and Clinical Case Discussions - Andrei H. Iagaru
May 10, 2021
Details
18F-Fluciclovine in Biochemical Recurrent Prostate Cancer - Andrei H. Iagaru
May 10, 2021
Details
DNA Repair and PARP Inhibitor Therapy in Prostate Cancer - Veda Giri, Patrick Pilié, and Arpit Rao
July 23, 2020
Details
Integrating Genetics and Genomics into Treatment Decisions for Men with Prostate Cancer - Panagiotis Vlachostergios
July 10, 2020
Details
Personalized Approaches to the Treatment of Prostate Cancer - Kenneth Pienta and James Gulley
July 10, 2020
Details
Implementation of Germline Testing for Prostate Cancer - Veda Giri
July 5, 2020
Details
Clinical Understanding of PARP Inhibitors in Prostate Cancer - Elena Castro, Wassim Abida, and Karen Knudsen
June 2, 2020
Details
Novel Radiopharmaceuticals In Development For Treatment in Advanced Prostate Cancer - Michael Morris
May 31, 2020
Details
Best of ASCO 2020 Prostate Cancer - Oliver Sartor
May 31, 2020
Details
PARP Inhibition in Castration-Resistant Prostate Cancer - Daniel Petrylak
May 24, 2020
Details
PARP Inhibitors Changing the Standard of Care for Treatment of Metastatic Prostate Cancer (mCRPC) - The PROfound Study
May 9, 2020
Details
TheraP Trial Design Evaluating 177Lu‐PSMA‐617 Theranostic Treatment vs Cabazitaxel in Progressive Metastatic Castration‐Resistant Prostate Cancer - Michael Hofman
May 8, 2020
Details
Genetically Informed Treatment for Advanced and Metastatic Prostate Cancer - Alicia Morgans
April 6, 2020
Details
Targeted Molecular Therapies for Treatment of Advanced Prostate Cancer - Scott Tagawa
March 30, 2020
Details
The Evolving Role of Lutetium-PSMA in the Era of Personalized Medicine - Michael Hofman
March 30, 2020
Details
Imaging and Flare Responses When Assessing Patients with Metastatic Castration-Resistant Prostate Cancer - Anwar Padhani
September 26, 2019
Details
Outcomes of Patients From PSMA Targeted Radionuclide Trials - Panagiotis Vlachostergios
August 8, 2020
Details
Integrating Germline and Somatic Mutations Tests into Clinical Practice Workflows - Wassim Abida
August 8, 2020
Details
High Activity Pain Reduction and Low Toxicity with Lu177 PSMA617 Theranostics - Michael Hofman
December 27, 2019
Details
The VISION Trial: Radionuclide Therapy Plus Standard Therapy for Metastatic Castration Resistant Prostate Cancer - Oliver Sartor and Michael Morris
November 18, 2019
Details
177LU-PSMA-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer - Oliver Sartor
October 31, 2019
Details
A Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer - The VISION Trial, Interview with Oliver Sartor
October 14, 2019
Details
PROfound Study - PARP-inhibitor Olaparib in Advanced Prostate Cancer Patients with Specific Tumor Mutations - Maha Hussain
October 10, 2019
Details
PSMA Targeted Therapies Presentation - Michael Hofman
September 18, 2019
Details
Theranostic Approaches for Advanced Prostate Cancer - Michael Hofman
February 25, 2019
Details
Role of PARP Inhibitors in Prostate Cancer - Evan Yu
February 5, 2019
Details
Effectiveness and Resistance to PSMA Targeted RadioLigand Therapy using 177 Lu-PSMA-617 - Jeremie Calais
February 4, 2019
Details
Diagnostic Imaging and Therapeutic Aspect of PSMA in Prostate Cancer by Michael Hofman
December 2, 2018
Details
Results from TRITON2: Treatment of mCRPC with Rucaparib - Alan Bryce
November 29, 2018
Details
State of the Art: Treatment Update in Prostate Cancer- Oliver Sartor
November 2, 2018
Details
PSMA Imaging and Theranostics: Future Impact to Patient Management– Robert Flavell
August 15, 2018
Details
email news signup